tbuckley/cabot-search huggingface dataset:
Abstract OT2-03-03: A randomized trial of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation
Authors: RW Mutter, SS Park, TJ Hieken, CE Vargas, PC Mei-Yin, RJ Kathryn, VR Hector, CS Kimberly, YS Elizabeth, VW Daniel
Journal: Cancer Research (2017)

Abstract Background: Post-mastectomy radiotherapy improves survival in women with node-positive breast cancer. Pencil beam scanning proton therapy is attractive due to potential to reduce the dose to the heart and lungs compared with traditional photon techniques while improving conformality and limiting skin dose compared with passively scanned proton therapy. The optimal dose and fractionation for pencil-beam scanning proton therapy remains unknown. Trial Design: This is a multi-center open label phase II randomized controlled trial to determine the safety of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation. Eligibility Criteria: Patients ≥ 18 years with primary, non-inflammatory invasive breast cancer who have undergone mastectomy with or without immediate reconstruction and chest wall and regional nodal irradiation planned. Aims: To determine whether the 24 month complication rate (defined as grade 3 or greater late adverse events, and unplanned surgical intervention in patients who undergo mastectomy with reconstruction) of 15 fraction chest wall and regional node pencil beam scanning proton radiotherapy is acceptable relative to 25 fraction chest wall and regional nodal pencil beam scanning proton radiotherapy and worthy of further investigation. Statistical methods: The study is designed as a non-inferiority/superiority “hybrid” design using the approach of Freidlin et al. It is Using a one-sided type I error rate of 0.05 (corresponding equivalently to constructing a 1-sided 95% confidence limit), 72 evaluable patients will have 80% power to reject the null hypothesis that the 24-month complication rate in the experimental arm is higher than that of the control arm by more than 10% (i.e. rule out inferiority) under the alternative hypothesis that the complication rate in the experimental arm is 5% less than that of the control arm (i.e. superiority). However, the design will have only 41% power when the two treatment arms are equivalent (i.e. the complication rate is 10% for both arms). Accrual: The study opened in June 2016. Five of a planned eighty-two patients have been accrued to date. Citation Format: Mutter RW, Park SS, Hieken TJ, Vargas CE, Mei-Yin PC, Kathryn RJ, Hector VR, Kimberly CS, Elizabeth YS, Daniel VW. A randomized trial of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-03-03.
RIZ1 Tumor Suppressor Regulates IGF-1 Autocrine Loop To Control Cell Proliferation, Apoptosis, and Differentiation in Chronic Myeloid Leukemia Blast Crisis Cell Lines.
Authors: Naoto Takahashi, Wei-Feng Dong, Matthew Bainbridge, Andrea Hull, Elodie Pastural, Derek Pearson, David Sheridan, John DeCoteau, C. Ron Geyer
Journal: Blood (2005)
Concordance Between the Serum Levels of Interleukin-6, Microrna-21, and the Severity of Subjective Symptoms of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Authors: Bang-Ning Lee, Sergio Giralt, Evan Cohen, Matthew Galland, Tiffany Lafortune, Ibrahima Gning, Tito R Mendoza, Lori Williams, Jane Brown, Xin Shelley Wang, Richard E Champlin, Valen E Johnson, Charles Cleeland, James M Reuben
Journal: Blood (2010)
A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.
Authors: Anna Maria Di Giacomo, Diego Annesi, Paolo Antonio Ascierto, Luana Calabrò, Vanna Chiarion-Sileni, Riccardo Danielli, Michele Del Vecchio, Virginia Ferraresi, Pier Francesco Ferrucci, Ester Fonsatti, Michele Guida, Diana Giannarelli, Massimo Guidoboni, Mario Mandalà, Pietro Quaglino, Paola Queirolo, Cristina Maccalli, Giorgio Parmiani, Michele Maio
Journal: Journal of Clinical Oncology (2015)

TPS9090 Background: The anti-CTLA-4 monoclonal antibody (mAb), ipilimumab (Ipi) significantly improves the survival of metastatic melanoma (MM) patients (pts). In spite of their poor prognosis, initial studies have evaluated the therapeutic potential of Ipi also in MM pts with brain metastasis (BM), providing preliminary evidences of efficacy. Among these, the multicentric, phase 2, Italian Network for Tumor Biotherapy (NIBIT)-M1 trial, combining Ipi with fotemustine, showed initial signs of activity in a subset of 20 MM subjects with active BM, regardless of prior radiotherapy. Though limited by the number of pts enrolled, disease control in the brain was long lasting achieving a 3-year survival rate of 28% (Di Giacomo et al, Annals Oncol, 2014). Based these results and on the highly promising efficacy of Ipi in combination with nivolumab (Nivo) in MM patients without BM, the NIBIT-M2 study will further explore the efficacy of immunotherapy with check-point blocking mAb in MM pts with BM. Methods: The NIBIT-M2 is a randomized, phase 3, open-label, study that will enroll 168 MM pts with untreated, asymptomatic BM, ECOG performance status of 0 or 1, BRAF W/T or mutant disease. Pts will be randomized to receive fotemustine i.v. at 100 mg/m2 weekly for 3 weeks (wk), and q3 wk from week 9 (ARM A) or Ipi i.v. at 10 mg/kg q3 wk for 4 doses and once q12 wk from week 24 in combination with fotemustine (ARM B) or Ipi i.v. at 3 mg/kg q3 wk for 4 doses in combination with Nivo at 1 mg/kg q3 wk for 4 doses and then Nivo at 3 mg/kg q2 wk (ARM C). Primary objective is Overall Survival; secondary are safety, Disease Control Rate in and outside the brain, Objective Response Rate and Duration of Response evaluated using both the modified-WHO response criteria and the immune-related response criteria; progression Free Survival (PFS), 3- and 6-months Brain-PFS rate and Quality of Life will also be evaluated. Phenotypic and functional cellular and humoral translational studies will correlate the immunomodulatory activity of treatment with clinical outcomes. Seventeen pts have been enrolled to date. (EUDRACT # 2012-004301-27) Clinical trial information: 2012-004301-27.
Metformin in early breast cancer (BC): A prospective, open-label, neoadjuvant “window of opportunity” study.
Authors: Saroj Niraula, Ryan JO Dowling, Marguerite Enis, Martin Chang, Susan Done, Nicky Hood, Jaime Escallon, Wey Leong, David R. McCready, Michael Reedijk, Vuk Stambolic, Pamela Jean Goodwin
Journal: Journal of Clinical Oncology (2012)

1019 Background: There is growing evidence that metformin may exert anti-cancer effects through indirect (insulin-mediated) or direct (insulin-independent) mechanisms. Here, we report final results of a neo-adjuvant “window-of-opportunity” study of metformin in women with operable BC. Methods: Newly diagnosed, untreated, non-diabetic BC patients received metformin 500 mg tid after diagnostic core-biopsy until definitive surgery(no other treatment). Clinical [weight, symptoms, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C-30)] and biologic characteristics [insulin, glucose, homeostatic model assessment (HOMA), C-reactive protein (CRP), leptin] were compared pre- and post-metformin as were Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL, an apoptotic marker) and Ki67 (primary end-point) scored blinded by manual count of positive nuclear-staining. The planned sample-size of 40 patients gave 90% power to detect a 5.5 percentage point change in Ki67. Results: Thirty-nine patients were enrolled and mean age was 51 years; metformin was given for 18 days (median), range 13-40 days. Twenty patients had T1 and 19 T2/T3 tumors; 16 tumors were grade III; 24 were N0; 32 ER/PR positive, 5 HER-2 positive. Grade 1-2 self-limiting diarrhea, anorexia and abdominal distention occurred in 50%, 41% and 32%. EORTC QLQ scores were stable in all function domains and overall scores. Main study outcomes are tabulated here. Conclusions: Short-term preoperative metformin was well-tolerated and resulted in clinical and cellular effects in keeping with beneficial anti-cancer effects as demonstrated by improved insulin resistance (HOMA), decreased proliferation (ki67) and increased apoptosis (TUNEL). [Table: see text]
Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort
Authors: Paul J Hampel, Kari G. Chaffee, Simonetto A Douglas, Timothy G. Call, Wei Ding, Saad S Kenderian, Jose F. Leis, Asher A. Chanan-Khan, Deborah A. Bowen, Michael J Conte, Sara J Achenbach, Susan M. Schwager, Susan L. Slager, Neil E. Kay, Tait D. Shanafelt, Sameer A. Parikh
Journal: Blood (2016)
Abstract P5-09-08: Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in <i>BRCA1</i>
Authors: J Ponce, C Vigil, JM Araujo, C Castañeda, G Calderon, JL Buleje, O Acosta, P Danos, F Huaman, ML Guevara-Fujita, A Aguilar, JA Pinto, HL Gomez, R Fujita
Journal: Cancer Research (2017)

Abstract Background Breast cancer is the leading cancer in women worldwide, while in Peru is the second most frequent cancer with a high incidence of triple negative breast cancers (21%). There is no previous information about BRCA1/BRCA2 mutations in Peruvian high-risk breast cancer patients. Prior studies from International diagnostic laboratories only presented results of our population as a pooled Hispanic data. Our aim was to characterize mutations in BRCA1/BRCA2 genes in Peruvian patients with breast cancer with hereditary patterns. Methods We evaluated mutations in BRCA1/BRCA2 genes by Sanger sequencing and large genomic rearrangements by multiplex ligation-dependent probe amplification (MLPA) in 18 families with hereditary breast cancer criteria identified at the Breast Unit of Oncosalud-AUNA (Lima-Peru). Molecular analysis was done in the facilities of Genetics and Molecular Biology Center at the San Martin de Porres University (Lima-Peru). Results Sequencing identified 4 pathogenic mutations in 4/18 families, three previously detected (BRCA1: c.302-1G&amp;gt;C y c.815_824dup10; BRCA2: c.5946delT) and a novel germline mutation in exon 15 of BRCA1 (c.4647_4648dupAA, ClinVar SCV000256598.1) producing a frameshift variant. MLPA revealed 2 amplifications in exon 7 (duplication and triplication) in BRCA1 in unrelated patients with potential pathogenic effects, one of this co-existed with the BRCA2: c.5946delT mutation. In addition, three variants of uncertain significance were found (c.140G&amp;gt;T, in exon 5 of BRCA1 and c.464G&amp;gt;A and c.938C&amp;gt;T in exon 5 and 10 of BRCA2, respectively). Conclusions After a comprehensive evaluation we found an alteration rate of 27.8% (5/18) in BRCA1/BRCA2 in families with criteria for hereditary breast cancer. We reported BRCA1 c.4647_4648dupAA as a novel mutation. Further studies including a larger sample size of Peruvian patients should evaluate the prevalence or founder effect of this mutation in our population. Citation Format: Ponce J, Vigil C, Araujo JM, Castañeda C, Calderon G, Buleje JL, Acosta O, Danos P, Huaman F, Guevara-Fujita ML, Aguilar A, Pinto JA, Gomez HL, Fujita R. Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-09-08.
Abstract A40: A novel, biosynthetic 3D hydrogel system for breast cancer mechanobiology studies
Authors: Amy Elissa Blatt, Bita Carrion, Rhima M. Coleman
Journal: Cancer Research (2017)

Abstract Breast tumor cell-extracellular matrix (ECM) interactions drive malignant transformation, invasion, and metastasis of breast cancer cells and contribute to treatment resistance. The tumor microenvironment, composed of multiple ECM components, activate mechanochemical pathways associated with breast cancer progression and signaling of runt-related transcription factor 2 (Runx2). There is an urgent need to model these interactions in physiologically relevant three-dimensional (3D) models in vitro. We recently demonstrated that we can create 3D PEG hydrogel systems, containing type I collagen, Arg-Gly-Asp (RGD), and hyaluronic acid, whose stiffness can be tuned independent of the number of ECM components incorporated. In this study, we demonstrate that these hydrogels can be utilized to mimic the in vivo tumor microenvironment. We examined the behavior of breast cancer cell lines MDA-MB-231 (invasive) and MCF7 (non-invasive) as well as MCF10A (non-tumorigenic mammary epithelial cells) in our novel, biosynthetic hydrogel systems. We showed that these hydrogels supported growth for each cell line and formation of acinar structures over a 23-day period in vitro. In future studies, we will assess the migratory behaviors of these cell lines in vitro using microfluidic devices as well as Runx2 expression and activity to determine the influence of matrix physiochemical properties on the invasive potential of breast tumor cells. This novel, biosynthetic system represents a reproducible framework where tumor cell behavior may be quantified as a function of a complex system in which combined microenvironmental parameters, including matrix stiffness, ECM composition, and their interactions, are systematically varied. Citation Format: Amy Elissa Blatt, Bita Carrion, Rhima M. Coleman. A novel, biosynthetic 3D hydrogel system for breast cancer mechanobiology studies. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr A40.
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients.
Authors: Marco Ladetto, Gloria Pagliano, Ilaria Avonto, Loredana Santo, Simone Ferrero, Federica Cavallo, Monica Astolfi, Patrizia Pregno, Claudia Crippa, Anna Marina Liberati, Vincenzo Callea, Luca De Rosa, Antonietta Falcone, Mariella Grasso, Daniela Drandi, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2007)
The Diagnosis of Hydatidiform Mole, Malignant Hydatidiform Mole and Choriocarcinoma with Special Reference to the Diagnostic Value of Pelvic Arteriography: Ulf Borell, Ingmar Fernström, Gunnar Moberger, and Lars Ohlson. Springfield, Illinois: Charles C Thomas, Publisher, 1966. 109 pp. $9.75
Authors: Renate Soulen
Journal: Cancer Research (1967)
Impact On Mother-Baby Parameters in Total Nuclear and CD34+ Cell Count in Umbilical Cord Blood Banking.
Authors: Christian Villanueva, John Pando, Patricia Saenz, Hugo Rios, Maria Márquez, Ines Honda, Isabel Aranda, Ina Perez, Gabriela Vidal, Julia Huamani, Eva Obregón-Zegarra, Pedro Carrasco, Miriam Vidurrizaga, Jorge Castillo-Aguirre, Antonio Carrasco-Yalán
Journal: Blood (2009)
GASC1 expression to predict response to paclitaxel plus cisplatin in oesophageal squamous cell carcinoma.
Authors: Ruinuo Jia, Gang Liu, Xiaoshan Feng, Xiang Yuan, Shegan Gao, Na Li, Zhikun MA, Jinyu Kong, Yufeng WANG, Shuo Liang, Pengfei Zhang, Mengxi Zhang
Journal: Journal of Clinical Oncology (2015)

e15065 Background: GASC1 is a novel driver oncogene involved in the development of multiple cancers. Our preliminary study reported GASC1 contributed to the occurrence and progression of esophageal squamous cell carcinoma (ESCC). However, it remains unclear if GASC1 contributes to chemoresistance of ESCC. Methods: We evaluated GASC1 expression immunohistochemically in biopsy specimens from 60 patients with ESCC (clinical stag II-‡W ), who received adjuvant chemotherapy with TP regiment, and compared clinical response rate (cRR, including clinical complete response (cCR) and partial response (cPR)), pathological complete response rate (pCRR) and over survival (OS) between the GASC1-positive and GASC1-negative groups. We also studied susceptibility of GASC1-suppressed ESCC cells to TP. Fisher’s exact test was performed for data analyses. P < 0.05 was considered to be significant. Results: GASC1 positive expression rate is 50% in ESCC before chemotherapy. The cRR and pCRR in GASC1- negative group were all significantly better than GASC1-positive group respectively (66.7% (20/24) vs. 40% (12/36), p = 0.035; 25% (6/24) vs. 0, p = 0.003). The rate of GASC1 positive expression correlate positively to the advanced clinical stage (II, III, ‡W respectively: 16.7%, 50%, 33.3% vs. 62.5%, 29.2%, 8.3%, p = 0.001), lymph node metastasis (69.4% vs. 37.5%, p = 0.014), and the higher pathologic grade (G1, G2, G3-4 respectively: 36.1%, 27.8 %, 36.1% vs. 75%, 16.7%, 8.3%, p= 0.009). After 2 years follow-up, the mean survival was 34.875 months in GASC1-negative and 24.159 months in GASC1-positive group, the median survival was 28.453 months in GASC1-negative and 18.992 months in GASC1- positive group. We also found GASC1 inhibition could improve the susceptibility of ECSS cells KYSE30, KYSE70 and KYSE150 to TP. Conclusions: Expression of GASC1 may be a useful predictive marker for response to paclitaxel- basic adjuvant chemotherapy and prognosis in ESCC. GASC1 inhibitor is hopeful to benefit reversing chemotherapy resistance on ESCC. (Registered with observational trials, ChiCRT, registration number ChiCTR-OCH-14004541) Clinical trial information: ChiCTR-OCH-14004541.
Abstract P3-09-04: Beyond <i>CHEK2</i> in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in <i>CHEK2</i> mutation carriers
Authors: E Pohl, L Richters, J Hauke, C Ernst, S Kröber, D Niederacher, N Arnold, J Ramser, E Groß, A Gehrig, G Schmidt, V Dutrannoy, K Kast, E Hahnen, R Schmutzler
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Feasibility and Safety Profile of Intensive Consolidation with Clofarabine and Intermediate-Dose Cytarabine (CLARA) in Younger Patients with AML in First Complete Remission (AML-CR1).
Authors: Ida Lobe, Nicolas Boissel, Emmanuel Raffoux, Adrienne de Labarthe, Cécile Pautas, Stéphane de Botton, Xavier Thomas, Hervé Dombret
Journal: Blood (2007)
Hydroxyurea Induces Growth Inhibition in BCR-ABL1 T315I+ Clones and Synergizes with Ponatinib in Killing TKI-Resistant CML Cells
Authors: Mathias A Schneeweiss, Konstantin Byrgazov, Chantal B Lucini, Susanne Herndlhofer, Wolfgang R. Sperr, Thomas Lion, Gregor Hoermann, Michael W. Deininger, Peter Valent, Karoline V Gleixner
Journal: Blood (2016)
Early warning signs of MI are missed in one in eight admissions, study suggests
Authors: Susan Mayor
Journal: BMJ (2017)

Early warning signs may have been missed in 12% of patients admitted to hospital who subsequently died of a myocardial infarction (MI), a UK study has found.1

Acute MI is a leading cause of hospital admission, and rapid diagnosis and treatment have improved survival in recent years. But growing evidence shows that patients who have an MI after being admitted for another reason have less streamlined care and worse mortality than those admitted with a primary MI …
In Vivo Permanent Marking of Cells with RAG1 Activation History Demonstrates That Lymphoid and Myeloid Derived Dendritic Cells Operate an Identical Developmental Program after Their Lineage Commitment.
Authors: Yong Chong, Tadafumi Iino, Shin-ichi Mizuno, Hirokazu Shigematsu, Yojiro Arinobu, Hiromi Iwasaki, Koichi Akashi
Journal: Blood (2007)
Steroid-Sparing Effects of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Authors: Marc E. Rothenberg, Gerald J. Gleich, Florence E. Roufosse, Lanny J. Rosenwasser, Peter F. Weller
Journal: Blood (2006)
23rd World Congress on Psychosomatic Medicine, Glasgow, 2015
Authors: Mike Gow
Journal: Psychotherapy and Psychosomatics (2014)

The WCPM is held every 2 years with this being the first time it has ever been held in Scotland.The theme of the 2015 congress is 'The Psychosomatic Factor in Clinical Practice'.This reflects the increasing awareness and importance of psychosomatics within modern medicine and indeed all healthcare professions.At the 23rd WCPM in Glasgow you will attend seminars, advanced workshops, clinical case discussions, update and plenary lectures, oral communications and poster sessions on current international clinical approaches and research in psychosomatic medicine at the award-winning Scottish Exhibition and Conference Centre, which has been nominated as the 'Best UK Conference Centre' no less than 3 times in recent years and certainly lives up to its reputation as an outstanding conference venue.The 23rd WCPM will provide a stimulating academic programme held at a world class conference venue in a vibrant city in one of the most historical and beautiful countries in the world.
Neonatal Herpes Simplex Virus Infection in King County, Washington
Authors: John Sullivan-Bolyai
Journal: JAMA (1983)

The incidence of neonatal herpes simplex virus (HSV) infection in King County, Washington, has increased progressively from a rate of 2.6 per 100,000 live births to King County residents during the years 1966 through 1969 to 4.8, 7.4, and 11.9 cases per 100,000 live births for the years 1970 through 1973, 1974 through 1977, and 1978 through 1981, respectively. Detailed interviews of the parents of newborns with neonatal HSV-2 infection revealed clinically symptomatic genital herpes in the mother or father in 65% of the parents and serological and/or cultural evidence of HSV-2 infection in the mother in the other 35% of cases. Clinically symptomatic first episodes of genital herpes during pregnancy occurred in four of the mothers who were delivered of newborns with neonatal HSV-2 infection; two of the mothers were symptomatic at the time of birth. The other 16 interviewed mothers who delivered newborns with neonatal HSV-2 infection all had serological and/or cultural evidence of past HSV-2 infection but were asymptomatic at term. All six newborns with neonatal HSV-1 infection acquired the disease from nongenital sources, and two newborns seemed to have acquired the disease from nonmaternal sources. These data indicate that detailed interviews of the parents are often useful in increasing the clinician's index of suspicion for neonatal HSV infection. The increased prevalence of genital HSV infection in the United States seems to be associated with a concomitant increase in neonatal HSV infection. (<i>JAMA</i>1983;250:3059-3062)